Updated list of our EC-8042 publications…
26
- Mithramycin delivery systems to develop effective therapies in sarcomas
- Estupiñán Ó, Niza E, Bravo I, Rey V, Tornín J, Gallego B, Clemente-Casares P, Moris F, Ocaña A, Blanco-Lorenzo V, Rodríguez-Santamaría M, Vallina-Álvarez A, González MV, Rodríguez A, Hermida-Merino D, Alonso-Moreno C, Rodríguez R.
- J Nanobiotechnology. 2021,19(1), 267. doi: 10.1186/s12951-021-01008-x. PMID: 34488783
25
- Nano-Encapsulation of Mithramycin in Transfersomes and Polymeric Micelles for the Treatment of Sarcomas
- Estupiñán Ó, Rendueles C, Suárez P, Rey V, Murillo D, Morís F, Gutiérrez G, Blanco-López MDC, Matos M, Rodríguez R.
- J Clin Med. 2021 Mar 25;10(7):1358. doi: 10.3390/jcm10071358. PMID: 33806182
24
- Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor
- Chasse MH, Johnson BK, Boguslawski EA, Sorensen KM, Rosien JE, Kang MH, Reynolds CP, Heo L, Madaj ZB, Beddows I, Foxa GE, Kitchen-Goosen SM, Williams BO, Triche TJ Jr, Grohar PJ.
- EMBO Mol Med. 2021 Feb 5;13(2):e12640. doi: 10.15252/emmm.202012640. PMID: 33332735
23
- Mithramycin A and mithralog EC-8042 inhibit SETDB1 expression and its oncogenic activity in malignant melanoma
- Federico A, Steinfass T, Larribère L, Novak D, Morís F, Núñez LE, Umansky V, Utikal J.
- Mol Ther – Oncolytics 2020 Jun 4;18:83-99 doi: 10.1016/j.omto.2020.06.001. PMID: 32637583
22
- CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma
- Flores G, Everett JH, Boguslawski EA, Oswald BM, Madaj ZB, Beddows I, Dikalov S, Adams M, Klumpp-Thomas CA, Kitchen-Goosen SM, Martin SE, Caplen NJ, Helman LJ, Grohar PJ.
- Mol Cancer Ther. 2020 May;19(5):1183-1196. doi: 10.1158/1535-7163.MCT-19-0775. PMID:32127464
21
- SOX2 Expression and Transcriptional Activity Identifies a Subpopulation of Cancer Stem Cells in Sarcoma with Prognostic Implications
- Menéndez ST, Rey V, Martínez-Cruzado L, González MV, Morales-Molina A, Santos L, Blanco V, Alvarez C, Estupiñán O, Allonca E, Rodrigo JP, García-Castro J, García-Pedrero JM, Rodríguez R.
- Cancers (Basel). 2020 Apr 13;12(4). pii: E964. doi: 10.3390/cancers12040964. PMID: 32295077
20
- The mithralog EC-7072 induces chronic lymphocytic leukemia cell death by targeting tonic B-cell receptor signaling pathway
- Lorenzo-Herrero S, Sordo-Bahamonde C, Bretones G, Payer AR, González-Rodríguez AP, González-García E, Pérez-Escuredo J, Villa-Álvarez M, Núñez LE, Morís F, Gonzalez S, López-Soto A
- Frontiers in immunology, 2019, 10, 2455. doi: 10.3389/fimmu.2019.02455. PMID: 31681329
19
- The SRC Inhibitor Dasatinib Induces Stem Cell-Like Properties in Head and Neck Cancer Cells that are Effectively Counteracted by the Mithralog EC-8042
- Hermida-Prado F, Villaronga MA, Granda-Díaz R, Del-Río-Ibisate N, Santos L, Hermosilla MA, Oro P, Allonca E, Agorreta J, Garmendia I, Tornín J, Perez-Escuredo J, Fuente R, Montuenga LM, Morís F, Rodrigo JP, Rodríguez R, García-Pedrero JM.
- J Clin Med. 2019 Aug 2;8(8). pii: E1157. doi: 10.3390/jcm8081157. PMID: 31382448
18
- Transcriptional Reprogramming and Inhibition of Tumor-propagating Stem-like Cells by EC-8042 in ERG-positive Prostate Cancer
- Shinde D, Albino D, Zoma M, Mutti A, Mapelli SN, Civenni G, Kokanovic A, Merulla J, Perez-Escuredo J, Costales P, Morís F, Catapano CV, Carbone GM
- European Urology Oncology 2019, 2(4), 415-424. doi: 10.1016/j.euo.2018.08.024. PMID: 31277777
17
- Factors Secreted by Cancer-Associated Fibroblasts that Sustain Cancer Stem Properties in Head and Neck Squamous Carcinoma Cells as Potential Therapeutic Targets
- Álvarez-Teijeiro S, García-Inclán C, Villaronga MA, Casado P, Hermida-Prado F, Granda-Díaz R, Rodrigo JP, Calvo F, Del-Río-Ibisate N, Gandarillas A, Morís F, Hermsen M, Cutillas P, García-Pedrero JM.
- Cancers (Basel). 2018 Sep 17;10(9). pii: E334. doi: 10.3390/cancers10090334
16
- Inhibition of SP1 by the Mithramycin Analog EC-8042 Efficiently Targets Tumor Initiating Cells in Sarcoma
- Tornin J, Martínez-Cruzado L, Santos L, Rodríguez A, Núñez L-E, Oro P, Hermosilla MA, Allonca E, Fernández-García MT, Astudillo A, Suárez C, Morís F, Rodríguez R.
- Oncotarget 2016, May 24;7(21):30935-50. doi: 10.18632/oncotarget.8817 PMID: 27105533
15
- ALDH1 expression and activity increase during tumor evolution in sarcoma cancer stem cell populations
- Martínez-Cruzado L, Tornin J, Santos L, Rodríguez A, García-Castro J, Morís F, Rodríguez R.
- Sci. Rep. 2016, Jun 13;6:27878. doi: 10.1038/srep27878 PMID: 27292183
14
- Identification of mithramycin analogs with improved targeting of the EWS-FLI1 transcription factor
- Osgood CL, Maloney N, Kidd CG, Kitchen-Goosen S, Segars E, Gebregiorgis M, Woldemichael GM, He M, Sankar S, Lessnick SL, Kang MH, Smith MA, Turner L, Madaj ZB, Winn ME, Núñez LE, González-Sabín J, Helman LJ, Morís F, Grohar PJ.
- Clinical Cancer Res. 2016, 22(16):4105-18. doi: 10.1158/1078-0432 PMID: 26979396
13
- Pleiotropic anti-angiogenic and anti-oncogenic activities of the novel mithralog demycarosyl-3D-ß-D-digitoxosyl-mithramycin SK (EC-8042)
- Fernández-Guizán A, Acebes-Huerta A, Huergo-Zapico L, López-Soto A, Núñez L-E, Morís F, González S.
- PLoS ONE, 2015, Nov 4;10(11):e0140786. doi:10.1371/journal.pone.0140786. PMID: 26536461
12
- Expanding the Chemical Diversity of the Antitumoral Compound Mithramycin by Combinatorial Biosynthesis and Biocatalysis: The Quest for Mithralogs with Improved Therapeutic Window
- Méndez C, González-Sabín J, Morís F, Salas JA.
- Planta Med. 2015 81(15), 1326-1338. doi: 10.1055/s-0035-1557876. PMID: 26393942
11
- Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2
- Pandiella A, Morís F, Ocaña A, Núñez LE, Montero JC.
- Oncotarget 2015, 6(32), 32856-67. doi: 10.18632/oncotarget.5942. PMID: 26439989
10
- Cytotoxic effects of mithramycin DIG-MSK can depend on the rise of autophagy
- Vizcaíno C, Rodríguez-Sánchez MA, Núñez LE, Morís F, Portugal J.
- Toxicol. in vitro. 2015 Oct;29(7):1537-44. doi: 10.1016/j.tiv.2015.06.008. PMID: 26079942
9
- Genome-wide modulation of gene transcription in ovarian carcinoma cells by a new mithramycin analogue
- Vizcaíno C, Núñez LE, Morís F, Portugal J.
- PLoS One. 2014 Aug 11;9(8):e104687. doi: 10.1371/journal.pone.0104687. PMID: 25110883
8
- The activity of a novel mithramycin analog is related to its binding to DNA, cellular accumulation, and inhibition of Sp1-driven gene transcription
- Fernández-Guizán A, Mansilla S, Barceló F, Vizcaíno C, Núñez LE, Morís F, González S, Portugal J.
- Chem. Biol. Interact. 2014 Jun 4;219C:123-132. doi: 10.1016/j.cbi.2014.05.019. PMID: 24907531
7
- Exploring Novel Opportunities for Aureolic Acids as Anticancer Drugs
- González-Sabín J, Morís F.
- Biochem. & Pharmacol. 2013, 2:e140. doi: 10.4172/2167-0501.1000e140
6
- Novel mithramycins abrogate the involvement of protein factors in the transcription of cell cycle control genes
- Vizcaíno C, Mansilla S, Núñez LE, Méndez C, Salas JA, Morís F, Portugal J.
- Biochem. Pharmacol. 2012 Nov1;84(9):1133-42. doi: 10.1016/j.bcp.2012.08.003. PMID: 22981341
5
- Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer
- Malek A, Núñez LE, Magistri M, Brambilla L, Jovic S, Carbone GM, Morís F, Catapano CV.
- PLoS One. 2012;7(4):e35130. doi: 10.1371/journal.pone.0035130. PMID:22545098
4
- Lipase-catalyzed preparation of chromomycin A₃ analogues and biological evaluation for anticancer activity
- González-Sabín J, Núñez LE, Menéndez N, Braña AF, Méndez C, Salas JA, Gotor V, Morís F.
- Bioorg. Med. Chem. Lett. 2012 Jul 1;22(13):4310-3. doi: 10.1016/j.bmcl.2012.05.015. PMID: 22647722
3
- Regioselective Enzymatic Acylation of Aureolic Acids to Obtain Novel Analogues with Improved Antitumor Activity
- González-Sabín J, Núñez LE , Braña AF, Méndez C, Salas JA, Gotor V, Morís F.
- Adv. Synth. Catal. 2012, 354, 1500 – 1508. doi: 10.1002/adsc.201100944
2
- A novel mithramycin analogue with high antitumor activity and less toxicity generated by combinatorial biosynthesis
- Núñez LE, Nybo SE, González-Sabín J, Pérez M, Menéndez N, Braña AF, Shaaban KA, He M, Morís F, Salas JA, Rohr J, Méndez C.
- Med. Chem. 2012 Jun 28;55(12):5813-25. doi: 10.1021/jm300234t. PMID: 22578073
1
- The chromomycin CmmA acetyltransferase: a membrane-bound enzyme as a tool for increasing structural diversity of the antitumour mithramycin
- García B, González-Sabín J, Menéndez N, Braña AF, Núñez LE, Morís F, Salas JA, Méndez C.
- Microb. Biotechnol. 2011 Mar;4(2):226-38. doi: 10.1111/j.1751-7915.2010.00229.x. PMID: 21342468